These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22963803)

  • 1. Probing the protective effects of a conformationally constrained nicotine vaccine.
    Moreno AY; Azar MR; Koob GF; Janda KD
    Vaccine; 2012 Oct; 30(47):6665-70. PubMed ID: 22963803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical evaluation of a nicotine vaccine within a self-administration behavioral model.
    Moreno AY; Azar MR; Warren NA; Dickerson TJ; Koob GF; Janda KD
    Mol Pharm; 2010 Apr; 7(2):431-41. PubMed ID: 20104903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccines for nicotine dependence.
    Maurer P; Bachmann MF
    Curr Opin Mol Ther; 2006 Feb; 8(1):11-6. PubMed ID: 16506520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expecting the antinicotine vaccine].
    Didilescu C
    Pneumologia; 2009; 58(3):177-8. PubMed ID: 19817315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.
    McCluskie MJ; Pryde DC; Gervais DP; Stead DR; Zhang N; Benoit M; Robertson K; Kim IJ; Tharmanathan T; Merson JR; Davis HL
    Int Immunopharmacol; 2013 May; 16(1):50-6. PubMed ID: 23562759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine conjugate vaccine as a novel approach to smoking cessation.
    Ottney AR
    Pharmacotherapy; 2011 Jul; 31(7):703-13. PubMed ID: 21923458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
    Hatsukami DK; Rennard S; Jorenby D; Fiore M; Koopmeiners J; de Vos A; Horwith G; Pentel PR
    Clin Pharmacol Ther; 2005 Nov; 78(5):456-67. PubMed ID: 16321612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.
    Laudenbach M; Tucker AM; Runyon SP; Carroll FI; Pravetoni M
    Vaccine; 2015 Nov; 33(46):6332-9. PubMed ID: 26409811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates.
    McCluskie MJ; Thorn J; Mehelic PR; Kolhe P; Bhattacharya K; Finneman JI; Stead DR; Piatchek MB; Zhang N; Chikh G; Cartier J; Evans DM; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Apr; 25(2):518-27. PubMed ID: 25737198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent progress in vaccines against nicotine addiction].
    Wang GB; Zhu CJ
    Yao Xue Xue Bao; 2013 Aug; 48(8):1189-94. PubMed ID: 24187824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats.
    Pentel PR; Dufek MB; Roiko SA; Lesage MG; Keyler DE
    J Pharmacol Exp Ther; 2006 May; 317(2):660-6. PubMed ID: 16407464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new strategy for improved nicotine vaccines using conformationally constrained haptens.
    Meijler MM; Matsushita M; Altobell LJ; Wirsching P; Janda KD
    J Am Chem Soc; 2003 Jun; 125(24):7164-5. PubMed ID: 12797775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.
    Wagena EJ; de Vos A; Horwith G; van Schayck CP
    Nicotine Tob Res; 2008 Jan; 10(1):213-8. PubMed ID: 18188762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The vaccine against nicotine--the future for smoking cessation?].
    Mihăltan F
    Pneumologia; 2007; 56(2):101-3. PubMed ID: 18019757
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates.
    McCluskie MJ; Thorn J; Gervais DP; Stead DR; Zhang N; Benoit M; Cartier J; Kim IJ; Bhattacharya K; Finneman JI; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Dec; 29(2):663-671. PubMed ID: 26404190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.
    Maurer P; Jennings GT; Willers J; Rohner F; Lindman Y; Roubicek K; Renner WA; Müller P; Bachmann MF
    Eur J Immunol; 2005 Jul; 35(7):2031-40. PubMed ID: 15971275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice.
    Pryde DC; Jones LH; Gervais DP; Stead DR; Blakemore DC; Selby MD; Brown AD; Coe JW; Badland M; Beal DM; Glen R; Wharton Y; Miller GJ; White P; Zhang N; Benoit M; Robertson K; Merson JR; Davis HL; McCluskie MJ
    PLoS One; 2013; 8(10):e76557. PubMed ID: 24098532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.
    Zhao Z; Powers K; Hu Y; Raleigh M; Pentel P; Zhang C
    Biomaterials; 2017 Apr; 123():107-117. PubMed ID: 28167389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New prospects of nicotine dependence treatment--vaccines].
    Goniewicz ML; Koszowski B; Czogała J; Zymełka A
    Przegl Lek; 2006; 63(10):1114-8. PubMed ID: 17288232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.